Myobloc

Botulinum Toxin Type A (Botox, Botox Cosmetic, Myobloc, Dysport)... 

Parenteral Powder for solution, 100 units/vial Botulinum toxin type (Myobloc)... 

Surprisingly perhaps, given its extreme toxicity, botulinum toxin was introduced into medical practice in 1983 to treat patients with squint. Since then, its use has been expanded to include other disorders of muscle control suffered by patients with cerebral palsy or after a severe stroke where the brain cannot control the muscles, which may remain permanently contracted. Tiny amounts of the toxin are injected into the affected muscle, which then becomes paralyzed and, so, relaxed. There are several forms of the toxin that are now marketed as "Botox 7 (type A toxin) and Myobloc (type B toxin). More recently, Botox has been used in "cosmetic77 medicine as a way of reducing lines and wrinkles in the face due to aging. 

Callaway JE. Botulinum toxin type B (Myobloc) pharmacology and biochemistry. Clin Dermatol. 2004 22 23-28. 

Myobloc Botulinum toxin type B Elan Pharmaceuticals... 

Botulinum toxin is both a medication and a neurotoxin, produced by the bacterium Clostridium botulinum. It is the most toxic protein known. It can be used to treat muscle spasms, and is sold commercially under various names (Botox, Dysport, Myobloc, etc.). Botox Cosmetic and Vistabel are available for cosmetic treatment. The toxin protein consists... 

Myobloc is available premixed in a clear colorless to light yellow sterile solution. It is available in three dosing volumes 2,500 units/0.5 ml, 5,000 units/1 ml, and 10,000 units/2 ml. It can remain stable under refrigeration for up to 21 months. Myobloc exists at pH 5.6 when in aqueous solution. This relatively acidic pH can cause increased discomfort in patients during injection. Myobloc has been found to have a less complete or shorter duration of muscle paralysis compared with Botox. 

Botulinum toxin-B Myobloc (Elan) Cervical dystonia... 

Trade names Botox (Allergan) Dysport (Ipsen) Myobloc (Solstice)... 

BOTULINUM TOXIN TYPE B (Myobloc solution, injectable 5000 units/mL)... 

Arezzo, J.C. 2009. Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, NeuroBloc /Myobloc Unique features and findings, Toxicon 54(5), 690-696. 

US Food and Drug Administration. 2009. Update of safety review of OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). Available at http //www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ ucml74959.htm (accessed April 2, 2010). 

Nomenclature Although botulinum toxin is commonly known as botox , that name is in fact only one of the brand names of formulations in which botulinum toxins are available. This can cause considerable confusion. In July 2009 the US Food and Drug Administration approved the following revisions to the prescribing information of botulinum toxin products (Botox, Botox Cosmetic, and Myobloc) [53 ] ... 

The established drug names have also been changed, in order to reinforce individual potencies and prevent medication errors. The new name to replace botuli-num toxin type A is OnabotulinumtoxinA (marketed as Botox and Botox Cosmetic). The name that replaces botuhnum toxin type B is RimabotulinumtoxinB (marketed as Myobloc). The FDA has also approved another botuhnum toxin product in this class, AbobotulinumtoxinA... 

---